What are the indications, recommended dosing, contraindications, monitoring requirements, common adverse effects, and alternative treatments for Vyvanse (lisdexamfetamine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vyvanse (Lisdexamfetamine): Clinical Overview

Vyvanse is FDA-approved for ADHD in patients ≥6 years and moderate-to-severe binge eating disorder (BED) in adults, with methylphenidate remaining first-line for ADHD in most international guidelines, while lisdexamfetamine serves as an alternative stimulant option. 1

Approved Indications

Vyvanse has two FDA-approved indications 1:

  • ADHD: Adults and pediatric patients ≥6 years of age
  • Binge Eating Disorder: Adults only with moderate-to-severe BED

Important limitation: Vyvanse is NOT indicated for weight loss. Use of sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events 1.

Dosing Recommendations

ADHD (Adults and Pediatric ≥6 years) 1

  • Starting dose: 30 mg every morning
  • Titration: Increase by 10-20 mg weekly
  • Therapeutic range: 30-70 mg/day
  • Maximum dose: 70 mg/day

Binge Eating Disorder (Adults) 1

  • Starting dose: 30 mg every morning
  • Titration: Increase by 20 mg weekly
  • Therapeutic range: 50-70 mg/day
  • Maximum dose: 70 mg/day

Renal Impairment Adjustments 1

  • Severe renal impairment: Maximum 50 mg/day
  • End-stage renal disease (ESRD): Maximum 30 mg/day

Available Formulations 1

  • Capsules: 10,20,30,40,50,60,70 mg
  • Chewable tablets: 10,20,30,40,50,60 mg

Mechanism and Pharmacokinetics

Lisdexamfetamine is a prodrug that is therapeutically inactive until enzymatically hydrolyzed primarily in the blood to active d-amphetamine 2, 3. This conversion is unaffected by gastrointestinal pH and normal transit times 2. The prodrug design provides:

  • Duration of action: 12-14 hours (13 hours in children, 14 hours in adults) 2
  • Once-daily dosing: Consistent plasma concentrations throughout the day 4
  • Reduced abuse potential: Compared to immediate-release d-amphetamine due to slow, controlled release 3, 4

Contraindications

Absolute contraindications 1:

  • Known hypersensitivity to amphetamine products or Vyvanse ingredients (anaphylaxis, Stevens-Johnson Syndrome, angioedema, urticaria reported)
  • Current MAOI use or within 14 days of stopping MAOIs (risk of hypertensive crisis)

Warnings and Precautions

Boxed Warning: Abuse, Misuse, and Addiction 1

Vyvanse has high potential for abuse and misuse leading to substance use disorder. Before prescribing:

  • Assess each patient's risk for abuse, misuse, and addiction
  • Educate patients/families about risks and proper storage/disposal
  • Throughout treatment, reassess risk and monitor for signs of abuse

Cardiovascular Risks 1

Avoid use in patients with 1:

  • Known structural cardiac abnormalities
  • Cardiomyopathy
  • Serious cardiac arrhythmia
  • Coronary artery disease
  • Other serious cardiac disease

Sudden death has been reported in patients with structural cardiac abnormalities treated with CNS stimulants at recommended ADHD dosages 1.

Prior to treatment: Assess for presence of cardiac disease 1

During treatment: Monitor blood pressure and heart rate regularly. CNS stimulants cause mean increases of 2-4 mmHg in blood pressure and 3-6 bpm in heart rate, though some patients experience larger increases 1.

Psychiatric Adverse Reactions 1

Before initiating Vyvanse, screen for 1:

  • Risk factors for developing manic episodes
  • Comorbid or history of depressive symptoms
  • Family history of suicide, bipolar disorder, or depression

New psychotic or manic symptoms: May occur in ~0.1% of patients without prior psychiatric history. If symptoms occur (hallucinations, delusional thinking, mania), consider discontinuing Vyvanse 1.

Pre-existing psychosis: CNS stimulants may exacerbate behavior disturbance and thought disorder 1.

Growth Suppression in Pediatric Patients 1

Closely monitor height and weight in pediatric patients. Pediatric patients not growing or gaining weight as expected may need treatment interruption 1. Critical caveat: Pediatric patients <6 years experienced more long-term weight loss than patients ≥6 years 1.

Peripheral Vasculopathy 1

Careful observation for digital changes is necessary. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients developing signs/symptoms of peripheral vasculopathy, including Raynaud's phenomenon 1.

Tics and Tourette's Syndrome 1

Before initiating: Assess family history and clinically evaluate for tics or Tourette's syndrome. Regularly monitor for emergence or worsening. Discontinue if clinically appropriate 1.

Serotonin Syndrome 1

Increased risk when co-administered with serotonergic agents (SSRIs, SNRIs, triptans) or during overdose. If it occurs, discontinue Vyvanse and initiate supportive treatment 1.

Common Adverse Effects

ADHD Population (≥5% incidence, ≥2x placebo) 1:

  • Decreased appetite
  • Insomnia
  • Dry mouth
  • Decreased weight
  • Irritability
  • Nausea
  • Upper abdominal pain
  • Anxiety
  • Dizziness
  • Diarrhea
  • Vomiting

BED Population (≥5% incidence, ≥2x placebo) 1:

  • Dry mouth
  • Insomnia
  • Decreased appetite
  • Increased heart rate
  • Constipation
  • Feeling jittery
  • Anxiety

Most adverse events are mild to moderate in intensity and transient 3.

Drug Interactions

pH-Altering Agents 1

Acidifying agents (decrease amphetamine blood levels):

  • Gastrointestinal: Guanethidine, reserpine, glutamic acid HCl, ascorbic acid
  • Urinary: Ammonium chloride, sodium acid phosphate, methenamine salts

Alkalinizing agents (increase amphetamine blood levels):

  • Gastrointestinal: Sodium bicarbonate
  • Urinary: Acetazolamide, some thiazides

Adjust Vyvanse dosage accordingly when co-administered with pH-altering agents 1.

Place in Therapy

ADHD Treatment Algorithm

International guidelines position 5, 6:

  • First-line: Methylphenidate (MPH) remains first-line in most Asian guidelines (Malaysia, Singapore, India, Korea) 5
  • Japan: Lisdexamfetamine (LDX) is approved with maximum dose 70 mg/day 5
  • General approach: Stimulants (MPH or amphetamines) are first-line for ADHD when medication is indicated after behavioral/environmental interventions fail 6

Lisdexamfetamine-specific evidence 7, 8:

  • In EU, lisdexamfetamine is indicated for children ≥6 years when response to previous MPH is clinically inadequate 7
  • Demonstrated greater efficacy than atomoxetine (prospective comparison) and OROS-MPH (post hoc comparison) in treatment-inadequate responders 7
  • In adults, response was similar in treatment-naïve patients and those who failed previous ADHD therapies including MPH 8

Alternative Treatments

For ADHD 5, 6:

  • Other stimulants: Methylphenidate formulations (IR, ER, LA, OROS)
  • Non-stimulants: Atomoxetine, guanfacine extended-release, clonidine extended-release
  • Non-pharmacological: Parent training, academic interventions, social skills training, cognitive behavioral therapy, biofeedback

For BED 9:

  • GLP-1 agonists
  • Naltrexone
  • Antidepressants
  • Antiseizure medications

Note: Treatment guidelines for BED lack substantial recommendations beyond lisdexamfetamine 9.

Monitoring Requirements

Baseline Assessment 1

  • Cardiac disease screening (history, physical exam)
  • Psychiatric screening (psychosis, bipolar disorder, depression risk factors)
  • Family history assessment (tics, Tourette's syndrome)
  • Baseline blood pressure, heart rate, height, weight

Ongoing Monitoring 1

  • Blood pressure and heart rate at each visit
  • Height and weight in pediatric patients (closely monitor growth)
  • Signs/symptoms of abuse, misuse, addiction
  • Emergence of psychiatric symptoms
  • Digital changes (peripheral vasculopathy)
  • Tics or Tourette's symptoms

Special Populations

Pregnancy 1

May cause fetal harm.

Lactation 1

Breastfeeding not recommended.

Pediatric <6 years 1

Not indicated. Experienced more long-term weight loss than older children.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.